1140 related articles for article (PubMed ID: 18669465)
1. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
Langendijk JA; Doornaert P; Verdonck-de Leeuw IM; Leemans CR; Aaronson NK; Slotman BJ
J Clin Oncol; 2008 Aug; 26(22):3770-6. PubMed ID: 18669465
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
3. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer.
Jellema AP; Slotman BJ; Doornaert P; Leemans CR; Langendijk JA
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):751-60. PubMed ID: 17560735
[TBL] [Abstract][Full Text] [Related]
4. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer.
Langendijk JA; Doornaert P; Rietveld DH; Verdonck-de Leeuw IM; Leemans CR; Slotman BJ
Radiother Oncol; 2009 Feb; 90(2):189-95. PubMed ID: 19167120
[TBL] [Abstract][Full Text] [Related]
5. Quantifying radioxerostomia: salivary flow rate, examiner's score, and quality of life questionnaire.
Al-Nawas B; Al-Nawas K; Kunkel M; Grötz KA
Strahlenther Onkol; 2006 Jun; 182(6):336-41. PubMed ID: 16703289
[TBL] [Abstract][Full Text] [Related]
6. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
[TBL] [Abstract][Full Text] [Related]
7. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
9. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
Dirix P; Abbeel S; Vanstraelen B; Hermans R; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):385-92. PubMed ID: 19553033
[TBL] [Abstract][Full Text] [Related]
10. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
12. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
13. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
[TBL] [Abstract][Full Text] [Related]
14. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
[TBL] [Abstract][Full Text] [Related]
15. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
Meirovitz A; Murdoch-Kinch CA; Schipper M; Pan C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):445-53. PubMed ID: 16839705
[TBL] [Abstract][Full Text] [Related]
16. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire.
Lin SC; Jen YM; Chang YC; Lin CC
J Pain Symptom Manage; 2008 Aug; 36(2):141-8. PubMed ID: 18395402
[TBL] [Abstract][Full Text] [Related]
17. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires.
Jensen K; Bonde Jensen A; Grau C
Radiother Oncol; 2006 Mar; 78(3):298-305. PubMed ID: 16524633
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.
Meyer F; Fortin A; Gélinas M; Nabid A; Brochet F; Têtu B; Bairati I
J Clin Oncol; 2009 Jun; 27(18):2970-6. PubMed ID: 19451440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
